Literature DB >> 23838262

Potency matters: thresholds govern endocrine activity.

Christopher J Borgert1, Stephen P Baker, John C Matthews.   

Abstract

Whether thresholds exist for endocrine active substances and for endocrine disrupting effects of exogenous chemicals has been posed as a question for regulatory policy by the European Union. This question arises from a concern that the endocrine system is too complex to allow estimations of safe levels of exposure to any chemical with potential endocrine activity, and a belief that any such chemical can augment, retard, or disrupt the normal background activity of endogenous hormones. However, vital signaling functions of the endocrine system require it to continuously discriminate the biological information conveyed by potent endogenous hormones from a more concentrated background of structurally similar, endogenous molecules with low hormonal potential. This obligatory ability to discriminate important hormonal signals from background noise can be used to define thresholds for induction of hormonal effects, without which normal physiological functions would be impossible. From such thresholds, safe levels of exposure can be estimated. This brief review highlights how the fundamental principles governing hormonal effects - affinity, efficacy, potency, and mass action - dictate the existence of thresholds and why these principles also define the potential that exogenous chemicals might have to interfere with normal endocrine functioning.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endocrine active substances; Endocrine disruption; Endocrine pharmacology; Hormone affinity; Hormone efficacy; Hormone potency; Potency threshold

Mesh:

Substances:

Year:  2013        PMID: 23838262     DOI: 10.1016/j.yrtph.2013.06.007

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  13 in total

1.  Uncertainties in biological responses that influence hazard and risk approaches to the regulation of endocrine active substances.

Authors:  Joanne L Parrott; Poul Bjerregaard; Kristin E Brugger; L Earl Gray; Taisen Iguchi; Sarah M Kadlec; Lennart Weltje; James R Wheeler
Journal:  Integr Environ Assess Manag       Date:  2017-01-18       Impact factor: 2.992

Review 2.  Environmental toxicant exposure and menstrual cycle length.

Authors:  Karissa C Hammer; Alexis Veiga; Shruthi Mahalingaiah
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-12       Impact factor: 3.626

3.  A model for aryl hydrocarbon receptor-activated gene expression shows potency and efficacy changes and predicts squelching due to competition for transcription co-activators.

Authors:  Ted W Simon; Robert A Budinsky; J Craig Rowlands
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

4.  Toxicology: a discipline in need of academic anchoring--the point of view of the German Society of Toxicology.

Authors:  U Gundert-Remy; H Barth; A Bürkle; G H Degen; R Landsiedel
Journal:  Arch Toxicol       Date:  2015-08-28       Impact factor: 5.153

5.  A path forward in the debate over health impacts of endocrine disrupting chemicals.

Authors:  R Thomas Zoeller; Åke Bergman; Georg Becher; Poul Bjerregaard; Riana Bornman; Ingvar Brandt; Taisen Iguchi; Susan Jobling; Karen A Kidd; Andreas Kortenkamp; Niels E Skakkebaek; Jorma Toppari; Laura N Vandenberg
Journal:  Environ Health       Date:  2014-12-22       Impact factor: 5.984

Review 6.  Molecular signaling network motifs provide a mechanistic basis for cellular threshold responses.

Authors:  Qiang Zhang; Sudin Bhattacharya; Rory B Conolly; Harvey J Clewell; Norbert E Kaminski; Melvin E Andersen
Journal:  Environ Health Perspect       Date:  2014-08-12       Impact factor: 9.031

7.  Recommended approaches to the scientific evaluation of ecotoxicological hazards and risks of endocrine-active substances.

Authors:  Peter Matthiessen; Gerald T Ankley; Ronald C Biever; Poul Bjerregaard; Christopher Borgert; Kristin Brugger; Amy Blankinship; Janice Chambers; Katherine K Coady; Lisa Constantine; Zhichao Dang; Nancy D Denslow; David A Dreier; Steve Dungey; L Earl Gray; Melanie Gross; Patrick D Guiney; Markus Hecker; Henrik Holbech; Taisen Iguchi; Sarah Kadlec; Natalie K Karouna-Renier; Ioanna Katsiadaki; Yukio Kawashima; Werner Kloas; Henry Krueger; Anu Kumar; Laurent Lagadic; Annegaaike Leopold; Steven L Levine; Gerd Maack; Sue Marty; James Meador; Ellen Mihaich; Jenny Odum; Lisa Ortego; Joanne Parrott; Daniel Pickford; Mike Roberts; Christoph Schaefers; Tamar Schwarz; Keith Solomon; Tim Verslycke; Lennart Weltje; James R Wheeler; Mike Williams; Jeffrey C Wolf; Kunihiko Yamazaki
Journal:  Integr Environ Assess Manag       Date:  2017-01-27       Impact factor: 2.992

Review 8.  Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery?

Authors:  Jonathan Bisson; James B McAlpine; J Brent Friesen; Shao-Nong Chen; James Graham; Guido F Pauli
Journal:  J Med Chem       Date:  2015-10-27       Impact factor: 7.446

9.  Human-relevant potency threshold (HRPT) for ERα agonism.

Authors:  Christopher J Borgert; John C Matthews; Stephen P Baker
Journal:  Arch Toxicol       Date:  2018-04-09       Impact factor: 5.153

10.  Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?

Authors:  Herman Autrup; Frank A Barile; Sir Colin Berry; Bas J Blaauboer; Alan Boobis; Herrmann Bolt; Christopher J Borgert; Wolfgang Dekant; Daniel Dietrich; Jose L Domingo; Gio Batta Gori; Helmut Greim; Jan Hengstler; Sam Kacew; Hans Marquardt; Olavi Pelkonen; Kai Savolainen; Pat Heslop-Harrison; Nico P Vermeulen
Journal:  Arch Toxicol       Date:  2020-06-08       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.